GC Cell Corporation (KOSDAQ:144510)

Market Cap	303.55B
Revenue (ttm)	172.92B
Net Income (ttm)	-82.24B
Shares Out	15.03M
EPS (ttm)	-5,473.02
PE Ratio	n/a
Forward PE	n/a
Dividend	100.00 (0.50%)
Ex-Dividend Date	n/a

Volume	16,743
Average Volume	27,569
Open	20,200
Previous Close	20,200
Day's Range	20,150 - 20,550
52-Week Range	16,940 - 38,000
Beta	1.30
RSI	48.32
Earnings Date	Aug 14, 2025

About GC Cell

GC Cell Corporation develops cell therapy products. It also provides cell banking, sample inspection, clinical trial, and bio logistics services. Its main product is Immuncell-LC. GC Cell Corporation has strategic agreement with Lukas Biomedical Co., Ltd. to develop Cell therapy. The company was formerly known as Green Cross Lab Cell Corporation and changed its name to GC Cell Corporation in November 2021. GC Cell Corporation was founded in 2011 and is based in Yongin-si, South Korea.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2011
• Employees: 752
• Stock Exchange: KOSDAQ
• Ticker Symbol: 144510

Financial Performance

In 2024, GC Cell's revenue was 174.45 billion, a decrease of -6.98% compared to the previous year's 187.54 billion. Losses were -73.90 billion, 42368.9% more than in 2023.